argenx Vyvgart remains king in the land of FcRn/IgG
Last week, Biohaven (BHVN) and Immunovant (IMVT) reported updates on their clinical trajectories for candidate Vyvgart peers. Biohaven's interim Phase 1 data revealed lower than expected IgG lowering, and Immunovant decided to deprioritize its lead asset batoclimab in favour of a next-gen FcRn asset. In the meantime, Vyvgart sits high and mighty on its throne as competition struggles to advance. With a PDUFA date set for June 21, the addition of CIDP to the Vyvgart menu represents a near-term trigger. We reiterate our € 435 TP and Buy rating.Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.